Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: TMEM126A

Gene summary for TMEM126A

Gene summary.

Gene information	Species	Human
	Gene symbol	TMEM126A
	Gene ID	84233
	Gene name	transmembrane protein 126A
	Gene Alias	OPA7
	Cytomap	11q14.1
	Gene Type	protein-coding
	GO ID	GO:0006996
	UniProtAcc	Q9H061

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
84233	TMEM126A	LZE4T	Human	Esophagus	ESCC	6.38e-18	2.97e-01	0.0811
84233	TMEM126A	LZE7T	Human	Esophagus	ESCC	5.66e-05	1.66e-01	0.0667
84233	TMEM126A	LZE8T	Human	Esophagus	ESCC	4.66e-07	1.26e-01	0.067
84233	TMEM126A	LZE24T	Human	Esophagus	ESCC	8.12e-20	5.46e-01	0.0596
84233	TMEM126A	LZE6T	Human	Esophagus	ESCC	2.12e-03	2.22e-01	0.0845
84233	TMEM126A	P1T-E	Human	Esophagus	ESCC	2.81e-03	2.47e-01	0.0875
84233	TMEM126A	P2T-E	Human	Esophagus	ESCC	8.07e-17	1.92e-01	0.1177
84233	TMEM126A	P4T-E	Human	Esophagus	ESCC	3.05e-56	1.29e+00	0.1323
84233	TMEM126A	P5T-E	Human	Esophagus	ESCC	7.66e-37	8.07e-01	0.1327
84233	TMEM126A	P8T-E	Human	Esophagus	ESCC	3.92e-04	6.31e-02	0.0889
84233	TMEM126A	P9T-E	Human	Esophagus	ESCC	1.70e-24	3.98e-01	0.1131
84233	TMEM126A	P10T-E	Human	Esophagus	ESCC	9.06e-23	3.85e-01	0.116
84233	TMEM126A	P11T-E	Human	Esophagus	ESCC	1.06e-21	7.47e-01	0.1426
84233	TMEM126A	P12T-E	Human	Esophagus	ESCC	1.96e-27	4.83e-01	0.1122
84233	TMEM126A	P15T-E	Human	Esophagus	ESCC	1.69e-09	1.29e-01	0.1149
84233	TMEM126A	P16T-E	Human	Esophagus	ESCC	2.26e-24	4.85e-01	0.1153
84233	TMEM126A	P17T-E	Human	Esophagus	ESCC	7.93e-11	5.39e-01	0.1278
84233	TMEM126A	P19T-E	Human	Esophagus	ESCC	5.19e-15	7.38e-01	0.1662
84233	TMEM126A	P20T-E	Human	Esophagus	ESCC	9.70e-13	2.34e-01	0.1124
84233	TMEM126A	P21T-E	Human	Esophagus	ESCC	3.90e-61	1.28e+00	0.1617

Page: 1 2 3 4 5 6

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0033108110	Esophagus	ESCC	mitochondrial respiratory chain complex assembly	83/8552	93/18723	9.56e-19	1.05e-16	83
GO:0010257110	Esophagus	ESCC	NADH dehydrogenase complex assembly	50/8552	57/18723	3.78e-11	1.24e-09	50
GO:0032981110	Esophagus	ESCC	mitochondrial respiratory chain complex I assembly	50/8552	57/18723	3.78e-11	1.24e-09	50
GO:00331087	Liver	Cirrhotic	mitochondrial respiratory chain complex assembly	64/4634	93/18723	3.85e-19	7.79e-17	64
GO:00102577	Liver	Cirrhotic	NADH dehydrogenase complex assembly	42/4634	57/18723	1.06e-14	1.06e-12	42
GO:00329817	Liver	Cirrhotic	mitochondrial respiratory chain complex I assembly	42/4634	57/18723	1.06e-14	1.06e-12	42
GO:003310812	Liver	HCC	mitochondrial respiratory chain complex assembly	80/7958	93/18723	3.47e-18	4.15e-16	80
GO:001025712	Liver	HCC	NADH dehydrogenase complex assembly	50/7958	57/18723	1.50e-12	7.20e-11	50
GO:003298112	Liver	HCC	mitochondrial respiratory chain complex I assembly	50/7958	57/18723	1.50e-12	7.20e-11	50
GO:003310818	Oral cavity	OSCC	mitochondrial respiratory chain complex assembly	75/7305	93/18723	2.17e-16	1.68e-14	75
GO:001025718	Oral cavity	OSCC	NADH dehydrogenase complex assembly	45/7305	57/18723	8.53e-10	2.13e-08	45
GO:003298118	Oral cavity	OSCC	mitochondrial respiratory chain complex I assembly	45/7305	57/18723	8.53e-10	2.13e-08	45
GO:003310819	Oral cavity	LP	mitochondrial respiratory chain complex assembly	63/4623	93/18723	2.24e-18	4.13e-16	63
GO:001025719	Oral cavity	LP	NADH dehydrogenase complex assembly	41/4623	57/18723	7.93e-14	7.89e-12	41
GO:003298119	Oral cavity	LP	mitochondrial respiratory chain complex I assembly	41/4623	57/18723	7.93e-14	7.89e-12	41
GO:003310824	Skin	cSCC	mitochondrial respiratory chain complex assembly	64/4864	93/18723	5.48e-18	6.58e-16	64
GO:001025724	Skin	cSCC	NADH dehydrogenase complex assembly	42/4864	57/18723	6.46e-14	4.09e-12	42
GO:003298124	Skin	cSCC	mitochondrial respiratory chain complex I assembly	42/4864	57/18723	6.46e-14	4.09e-12	42
GO:0033108111	Thyroid	PTC	mitochondrial respiratory chain complex assembly	65/5968	93/18723	5.60e-14	3.21e-12	65
GO:0010257111	Thyroid	PTC	NADH dehydrogenase complex assembly	43/5968	57/18723	1.73e-11	6.81e-10	43

Page: 1 2

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

TMEM126A

SNV

Missense_Mutation

c.151N>C

p.Asn51His

p.N51H

Q9H061

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-A1-A0SO-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

TMEM126A

SNV

Missense_Mutation

novel

c.273N>T

p.Leu91Phe

p.L91F

Q9H061

protein_coding

deleterious(0)

probably_damaging(0.99)

TCGA-C8-A26Y-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

TMEM126A

SNV

Missense_Mutation

rs765038408

c.409N>G

p.Leu137Val

p.L137V

Q9H061

protein_coding

tolerated(0.62)

benign(0.007)

TCGA-C5-A905-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

TMEM126A

SNV

Missense_Mutation

c.9N>G

p.Asn3Lys

p.N3K

Q9H061

protein_coding

deleterious(0.01)

benign(0.11)

TCGA-FU-A3HZ-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

TMEM126A

SNV

Missense_Mutation

c.218N>T

p.Gly73Val

p.G73V

Q9H061

protein_coding

tolerated(1)

benign(0)

TCGA-AD-A5EJ-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

TMEM126A

insertion

Nonsense_Mutation

novel

c.390_391insAACATGATTTAAAGAAT

p.Ala131AsnfsTer4

p.A131Nfs*4

Q9H061

protein_coding

TCGA-AM-5820-01

Colorectum

colon adenocarcinoma

Female

<65

I/II

Unknown

TMEM126A

SNV

Missense_Mutation

novel

c.514N>C

p.Tyr172His

p.Y172H

Q9H061

protein_coding

deleterious(0)

probably_damaging(0.99)

TCGA-A5-A0GR-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

TMEM126A

SNV

Missense_Mutation

novel

c.188N>A

p.Ala63Asp

p.A63D

Q9H061

protein_coding

deleterious(0)

probably_damaging(0.939)

TCGA-A5-A1OF-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

TMEM126A

SNV

Missense_Mutation

rs377476349

c.190N>T

p.Arg64Cys

p.R64C

Q9H061

protein_coding

tolerated(0.11)

possibly_damaging(0.828)

TCGA-AP-A1DV-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

TMEM126A

SNV

Missense_Mutation

novel

c.514T>C

p.Tyr172His

p.Y172H

Q9H061

protein_coding

deleterious(0)

probably_damaging(0.99)

TCGA-AX-A0IZ-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

Page: 1 2

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1